CTS SCIENTIFIC PROGRAM 2016. Monday ... Held in conjunction with CHEST 2016 ... Respirology-the Next Generation: Using S
CTS SCIENTIFIC PROGRAM 2016 Monday October 24th, 11:00 – 17:30 Held in conjunction with CHEST 2016 Los Angeles Convention Centre - Room 403A, Los Angeles, California Program Chair: Dr. John Gjevre 11:00 – 11:20
What’s new in Interventional Pulmonology? Dr. Sébastien Ba Thien Nguyen, University of Montreal This session will focus on novelties in interventional pulmonology with an emphasis on bronchoscopic lung volume reduction. After attending this session, the learner will be able to: Discuss the role of interventional pulmonology in the management of COPD patients Review emerging modalities studied in bronchoscopic lung volume reduction Identify advantages and limitations of bronchoscopic lung volume reduction in COPD patients
11:20 – 11:40
Respirology-the Next Generation: Using Social Media Tools to Enhance Education Dr. Anju Anand, University of Toronto Social media, defined as internet-based applications that allow for the creation and exchange of user-generated content, have changed how people engage with one another. From connecting with others through social networking sites such as Facebook or LinkedIn, to sharing images on Instagram or sharing ideas via Twitter, YouTube, wikis, podcasting or a host of other social media tools, social media use has exploded over the last decade. In medicine, connecting, collaborating and communicating with other health care professionals, patients and the public is key. Yet, physicians have generally been slow to adopt technological advances to practice. Often this is due to perceived legal or professional consequences or general fear surrounding the use of technology. Interestingly, many physicians do not realize that even as nonusers, they already have a digital shadow so participating and understanding newer technologies can often result in greater control over content and enhance professional safeguards. This talk will review the guidelines for appropriate use of social media for physicians. In addition, it will highlight some of ways members in Respirology are using social media to enhance education, research and awareness with a special focus given to Twitter. After attending this session, the learner will be able to: Summarize the key components involved in the appropriate use of social media amongst medical professionals Review how professionals in Respirology are currently using social media tools to advance the field Describe of the basics of using social media tools such as Twitter
11:40 – 12:00
The Diagnostic Evaluation of Fibrotic Interstitial Lung Disease Dr. Kerri Johannson, University of Calgary The fibrotic interstitial lung diseases (ILDs) are a large and heterogeneous group of disorders that can be challenging to accurately diagnose. This session will present the current evidence for specific diagnostic modalities in the evaluation of fibrotic ILD, including chest imaging, serologic antibody testing and histopathologic sampling, with a focus on the Canadian practice landscape. After attending this session, the learner will be able to: Order appropriate chest imaging and serologic antibody tests as part of the diagnostic evaluation of fibrotic ILD Analyze the risk-benefit ratio of different histologic sampling modalities in the diagnostic evaluation of fibrotic ILD Review the importance of multi-disciplinary discussion in the diagnostic evaluation of fibrotic ILD
12:00 – 13:30
Break
13:30 – 14:00
Great Balls of Granulomas: Putting Out the Sarcoidosis Fire Dr. Meyer Balter, University of Toronto Sarcoidosis is a disease with a variable course, with the majority of patients eventually achieving spontaneous remission. However, there are subsets of patients in whom the disease is relentlessly progressive or in whom periods of relative disease quiescence are punctuated by exacerbations that can be severe or result in further loss of lung function. Recognizing patients who have active disease that is likely to result in physiologic and/or radiologic worsening and who may benefit from anti-inflammatory therapy can be challenging. There is no universal agreement on appropriate evaluation or therapy of these patients. Novel techniques, such as PET scanning, have been proposed for use in evaluating disease activity. In addition, the appropriate therapy for severe or progressive disease is speculative. The evidence supporting the use of non-steroidal therapies will be discussed. After attending this session, the learner will be able to: Evaluate disease activity in sarcoidosis Identify an appropriate treatment strategy for their patients with sarcoidosis
14:00 - 14:30
Tackling AVMs and Outcomes in Hereditary Hemorrhagic Telangiectasia Dr. Marie Faughnan, University of Toronto Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of arteriovenous malformations (AVMs), causing bleeding, stroke and heart failure. The diagnosis of HHT, pulmonary AVMs and other clinically significant aspects of HHT will be reviewed. Current treatment, emerging therapeutics and outcomes will be discussed. After attending this session, the learner will be able to: Diagnose pulmonary AVMs and HHT Describe the indications and methods for AVM treatment Review clinically important outcomes in HHT Discuss developing therapeutic approaches for HHT and AVMs
14:30 – 15:15
Break
15:15-16:15
Debate: ACOS (asthma COPD overlap syndrome): a neglected but valuable concept for improving our understanding and treatment of airways disease. Pro: Dr. Mark FitzGerald, University of British Columbia Con: Dr. Donald Cockcroft, University of Saskatchewan After attending this session, the learner will be able to: Review the definition of ACOS Discuss the importance of defining a group of patients with features of both asthma and COPD Describe the importance of phenotyping patients with airways disease
16:15 – 16:30
Break
16:30-17:30
2016 CTS Honorary Lecture: COPD: State of the Art Update for Clinicians Dr. Darcy Marciniuk, University of Saskatchewan This presentation will provide a state of the art update for clinicians in the management of COPD. The current burden of COPD will be shared, and past advances that guide current management strategies and therapies will be reviewed. The benefits of utilizing evidenceinformed pharmacologic and non-pharmacologic therapies, and a chronic disease management strategy, to improve lung function, activity, exercise, and quality of life, and reduce shortness of breath, as well as prevent acute exacerbations of COPD will be highlighted. Current controversies will be briefly discussed to provide context and assess their practical impact. Recent advances and the findings from ongoing clinical research in the field will also be addressed and summarized. After attending this session, the learner will be able to: Describe the current burden of COPD, and the factors contributing to that reality Identify effective evidence-informed goal-directed therapies to optimize patient care Review recent advances and the findings from ongoing clinical research in the field
18:30 – 20:00
CTS Members’ Reception (by invitation)
